<DOC>
	<DOCNO>NCT00384176</DOCNO>
	<brief_summary>The purpose study see Cediranib combination FOLFOX effective treating metastatic colorectal cancer see compare Avastin ( Bevacizumab ) combination FOLFOX .</brief_summary>
	<brief_title>First Line Metastatic Colorectal Cancer Therapy Combination With FOLFOX</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Clinical Diagnosis colon rectal cancer No prior systemic therapy metastatic disease . Any adjuvant/neoadjuvant oxaliplatin therapy must receive &gt; 12 month prior study entry adjuvant/neoadjuvant 5FU must receive &gt; 6 month prior study entry . Prior treatment VEGF Inhibitor , include bevacizumab cediranib . Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>